Inspection prep notes · Sterility and contamination control
Sterilization
Also called: autoclave, depyrogenation
FDA looks less at whether sterilization equipment is in place than at whether the sterilization process is validated and its effect and the state of items after sterilization are confirmed. The findings below are quoted from warning letters and FDA 483s.
What inspectors cited
1Did not validate the sterilization process or cycle
The (b)(4) sterilization process used for equipment that comes into direct contact with your products has not been adequately validated.
FDA Warning Letter · Neobiosis, LLC · 2024-06-18 · View document
In addition there is no data to support the validation/qualification of the autoclave cycle.
FDA 483 · Celltex Therapeutics Corporation · 2024-01-17 · View document
2Did not use or control biological indicators
Your firm lacked appropriate spore population verification on in-house prepared biological indicators (BIs) used in your (b)(4) sterilization (b)(4) process.
FDA Warning Letter · CareFusion 213, LLC · 2026-05-05 · View document
Operators do not use Biological Indicators (Bis) [redacted] sterilization [redacted].
FDA 483 · TAILSTORM HEALTH INC · 2026-09-29 · View document
3Did not integrity test every batch or did not report failing integrity test results
For example: On August 8, 2024, two operators performed four post-use sterilizing filter integrity tests for (b)(4) batch (b)(4) . The four tests included three failing results and the final passing result. Your operators only reported the passing result.
FDA Warning Letter · Aspen Pharmacare Holdings Limited · 2025-03-18 · View document
Sterilizing (b)(4) were not integrity tested for each batch of drug products manufactured.
FDA Warning Letter · BRS Analytical Services, LLC · 2025-10-21 · View document
4Did not sterilize and depyrogenate containers, closures or compounding equipment
Specifically, your firm does not sterilize/depyrogenate the glass beakers, [redacted] graduated cylinders, and stir bars used to make sterile drug products.
FDA 483 · Houston Rx LLC · 2026-10-01 · View document
Drug product containers and closures were not sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
FDA 483 · Hybrid Pharma LLC · 2026-11-13 · View document
5Did not establish a sterile hold time or could not tell whether it had been exceeded
Your cleaning validation did not establish the clean hold time (CHT) and sterile hold time (SHT) such that there is no assurance that your manufacturing equipment are free of/meet the specifications for microbiological and endotoxin levels at the time of manufacturing.
FDA 483 · Orchid Pharma Limited · 2026-04-09 · View document
The components lacked information identifying the applicable [redacted] and sterilization date needed for personnel to determine whether the established sterile hold time had been exceeded.
FDA 483 · OPS International Inc dba Olympia Pharmaceuticals · 2026-10-01 · View document
Questions to check against your procedures
- Is the sterilization process for equipment in direct contact with product validated?
- Is there data to support the validation and qualification of the autoclave cycle?
- Are biological indicators used in routine sterilization, and is the spore population of in-house prepared indicators verified?
- Are post-use sterilizing filter integrity tests done for every batch, and are failing results all recorded and reported?
- Are containers, closures and glassware sterilized and depyrogenated before use?
- Is a sterile hold time established, and can the sterilization date of each part be identified?
Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.